Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference
Rhea-AI Summary
Galecto (NASDAQ: GLTO) will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026 at 10:40 a.m. ET.
According to the company, management will webcast the presentation live and make an archived replay available for 30 days under the Investor Calendar on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – GLTO
In the Mar 2 session, GLTO gained 1.59%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Offering closed | Negative | -3.0% | Closed underwritten offering at $19.00 with full over-allotment exercise. |
| Feb 10 | Offering priced | Negative | +1.3% | Priced $275M common stock offering at $19.00 per share. |
| Feb 10 | Offering proposed | Negative | +1.3% | Proposed offering of common and Series C preferred stock for R&D funding. |
| Jan 12 | Strategic update | Positive | +6.4% | Outlined 2026 milestones and pipeline plans, supported by $285M PIPE runway. |
| Jan 06 | Leadership hires | Positive | +2.7% | Announced new COO and CMO and reiterated DMR-001 development timeline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Capital-raising offerings have produced mixed reactions, while strategic and leadership news skewed positive with supportive price moves.
Recent news for Galecto shows intensive capital and strategic activity. In January 2026, leadership additions and a 2026 milestones update, backed by a $285M PIPE, saw shares rise 2.73% and 6.44%. In February 2026, a proposed, priced, and then closed equity offering around $19.00 per share generated a modestly positive 1.3% reaction on announcement but a -3.03% move after closing. Today’s conference participation fits the non-price-moving, routine “news” category.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 at 10:40 a.m. ET.
A live webcast of the Company’s presentation will be available under the “News & Events” tab in the Investor Calendar section of the Company’s website at https://ir.galecto.com/news-and-events/events. An archived replay will be accessible for 30 days following the event.
About Galecto, Inc.
Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.
Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
